Erik Trock-Jansen
Amministratore Delegato presso NOVIMMUNE SA
Provenienza dei contatti di primo grado di Erik Trock-Jansen
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Subsidiary | Medical/Nursing Services | 7 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Erik Trock-Jansen tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| BB BIOTECH AG | Financial Conglomerates | Chairman Director/Board Member | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member | |
| ROCHE HOLDING AG | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal | |
| PAREXEL INTERNATIONAL CORPORATION | Miscellaneous Commercial Services | Director/Board Member | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
Corange Ltd.
 Corange Ltd. Pharmaceuticals: GenericHealth Technology Part of Roche Holding AG, Corange Ltd. is a Bermudian company that manufactures orthopedic and diagnostics equipment. The company is based in Hamilton, Bermuda. Corange was acquired by Roche Holding AG on May 01, 1997 for $10,930.22 million. | Pharmaceuticals: Generic | Director of Finance/CFO | |
Roche Holdings, Inc.
 Roche Holdings, Inc. Financial ConglomeratesFinance Roche Holdings, Inc. operates as a holding company, which engages in the manufacture and distribution of pharmaceutical and vitamin products. It also provides financial services to other members of the RHI Group and to refinance on the bond or loan markets. The company was founded in 1987 and is headquartered in San Francisco, CA. | Financial Conglomerates | Director/Board Member | |
| AC IMMUNE SA | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| TIGENIX NV | Medical Specialties | Director/Board Member | |
| CHUGAI PHARMACEUTICAL CO., LTD | Pharmaceuticals: Major | Director/Board Member | |
Diethelm Keller Holding AG
 Diethelm Keller Holding AG Miscellaneous Commercial ServicesCommercial Services Diethelm Keller Holding Ltd. holding company with interest in providing brand management, marketing, logistics and travel services. The firm brands include EDAK, Koenig, Turmix, Zyliss, Wetrok, Delta and Gloster. The company is headquartered in Zurich, Switzerland. | Miscellaneous Commercial Services | Chief Executive Officer | |
Debiopharm International SA
 Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | General Counsel | |
Roche Diagnostics GmbH
 Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999. | Miscellaneous Commercial Services | Director of Finance/CFO | |
| HBM HEALTHCARE INVESTMENTS AG | Investment Managers | Director/Board Member | |
| Rutgers State University of New Jersey | College/University | Undergraduate Degree | |
Roche Ventures
 Roche Ventures Investment ManagersFinance Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002. | Investment Managers | Director of Finance/CFO | |
| Ruprecht-Karls-Universität Heidelberg | College/University | Doctorate Degree | |
| University of Basel | College/University | Doctorate Degree | |
| University of Zurich | College/University | Doctorate Degree | |
| University of Geneva | College/University | Graduate Degree | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree | |
| International Institute for Management Development | College/University | Director/Board Member | |
| Medical College of Virginia | College/University | Doctorate Degree | |
Cellerix SA
 Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Director/Board Member | |
| Basel Institute for Immunology | College/University | Corporate Officer/Principal | |
| Serono Pharmaceutical Research Institute | Corporate Officer/Principal | ||
| Glaxo-Welcomes' Research Institute | Corporate Officer/Principal | ||
| Medabiotech | Chief Administrative Officer | ||
Pharmaq Holding AS
 Pharmaq Holding AS Financial ConglomeratesFinance Pharmaq Holding AS invests in shares, obligations, real properties, and other participations. The company was founded on February 22, 2013 and is headquartered in Overhalla, Norway. | Financial Conglomerates | Director/Board Member | |
Myelin Repair Foundation, Inc.
 Myelin Repair Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services Myelin Repair Foundation, Inc. is a non-profit organization that operates to provide funds for research that lead to publications of scientific articles. It offers discovery biology, translational medicine, and clinical researches. The company was founded by Scott Johnson in 2004 and is headquartered in Saratoga, CA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
AB2 Bio SA
 AB2 Bio SA Pharmaceuticals: MajorHealth Technology AB2 Bio SA develops and manufactures drugs. The firm's products include Interleukin-18 Binding Protein and Proprietary Assay. The company was founded in 2010 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
| Swiss Cancer Foundation | Director/Board Member | ||
Relais Colis SAS
 Relais Colis SAS Air Freight/CouriersTransportation Relais Colis SAS offers home delivery services. It offers its solution to the electronic commerce industry. It also provides customer and delivery tracking services to its clients. The company was founded in 1983 and is headquartered in Crétail, France. | Air Freight/Couriers | Chief Executive Officer | |
EngMab SARL
 EngMab SARL Pharmaceuticals: MajorHealth Technology EngMab SARL operates as a biotechnology company. It focuses on cancer immunotherapy and hematological malignancies and solid tumors. The company was founded by Klaus Strein in 2013 and is headquartered in Pfäffikon, Switzerland. | Pharmaceuticals: Major | Director/Board Member Founder | |
Ipsen Bioinnovation Ltd.
 Ipsen Bioinnovation Ltd. BiotechnologyHealth Technology Ipsen Bioinnovation Ltd. Engages in the research and development of pharmaceutical products. The company was founded in 2005 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Director/Board Member | |
LamKap Bio beta AG
 LamKap Bio beta AG BiotechnologyHealth Technology LamKap Bio beta AG specializes in research and development. It also focuses on licensing and marketing of medical therapies, in particular antibody-based therapies against cancer and diseases of the immune system. The company was founded on December 12, 2017 and is headquartered in Pfäffikon, Switzerland. | Biotechnology | Chairman Chairman | |
Berta Holding AG
 Berta Holding AG BiotechnologyHealth Technology Berta Holding AG engages in the research, development, production, licensing and marketing of pharmaceuticals. Its products include medicines and medical therapies, particularly antibody-based therapies for cancer, immune system disorders, and infectious diseases. The company was founded on September 03, 2018 and is headquartered in Pfäffikon, Switzerland. | Biotechnology | Chairman Director/Board Member | |
| Entsia International AG | Chairman | ||
| Discoveric AG | Chairman | ||
| Lamkap Bio Alpha AG | Chairman Chairman | ||
| Lamkap Bio Gamma AG | Chairman Chairman | ||
| discoveric marina AG | Chairman | ||
| discoveric bio alpha AG | Chairman | ||
| discoveric bio beta AG | Chairman | ||
| Discoveric Bio Gamma AG | Chairman | ||
| Discoveric Marketplace AG | Chairman |
Statistiche
Distribuzione geografica
| Svizzera | 31 |
| Stati Uniti | 7 |
| Germania | 4 |
| Francia | 3 |
| Bermuda | 2 |
Settori
| Health Technology | 15 |
| Consumer Services | 10 |
| Finance | 6 |
| Commercial Services | 5 |
| Non-Energy Minerals | 2 |
Posizioni
| Director/Board Member | 20 |
| Chairman | 18 |
| Corporate Officer/Principal | 8 |
| Director of Finance/CFO | 5 |
| Doctorate Degree | 5 |
Contatti più connessi
- Borsa valori
- Insiders
- Erik Trock-Jansen
- Connessioni Società
